Keloid Scarring: Treatment and Pathophysiology
This trial is active, not recruiting.
|Treatments||5- fluorouracil, radiotherapy, triamcinolone|
|Sponsor||Queen Mary University of London|
|Start date||February 2011|
|End date||January 2012|
|Trial size||100 participants|
|Trial identifier||NCT01295099, KS001|
To clarify the mechanisms of Keloid scar formation.
Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment
Identify the genetic link with Keloid scar formation.
Quantify the psychological/social impact in keloid scarring patients
|Intervention model||single group assignment|
Keloid Scar Reduction
time frame: 18 months
Male or female participants from 18 years up to 85 years old.
- Adult ( > 18 years old).
- Keloid scarring present.
- Able to understand and give informed consent.
- Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty).
- Patients with a strong familial pedigree of keloid scar formation.
- Open wound at or proximity of the lesion
- Infected lesion
- Pregnant or planning pregnancy in the near future
- Lactating (Breast Feeding)
- Abnormal renal or liver function tests
- Atrophic scars
- Patient under 18 years of age
- OR immunosuppressed
|Official title||Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease|
Call for more information